BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
177.88
+2.78 (1.59%)
Jan 8, 2025, 4:00 PM EST - Market closed
BeiGene Employees
BeiGene had 10,600 employees as of December 31, 2023. The number of employees increased by 1,600 or 17.78% compared to the previous year.
Employees
10,600
Change (1Y)
1,600
Growth (1Y)
17.78%
Revenue / Employee
$316,161
Profits / Employee
-$80,606
Market Cap
18.94B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amazon.com | 1,551,000 |
Berkshire Hathaway | 396,500 |
Berkshire Hathaway | 396,500 |
Microsoft | 228,000 |
Alphabet | 181,269 |
Alphabet | 179,582 |
Apple | 164,000 |
Tesla | 140,473 |
ONC News
- 3 days ago - BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe - Business Wire
- 13 days ago - TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy - Business Wire
- 17 days ago - BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 27 days ago - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire
- 4 weeks ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Business Wire
- 5 weeks ago - BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL - Business Wire
- 5 weeks ago - BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 - Business Wire
- 5 weeks ago - BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US - Seeking Alpha